Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study

Nephrology

Volumn 22, Issue 4, 2017, Pages 293-300

  Koiwa, Fumihiko ^a   Yokoyama, Keitaro ^b   Fukagawa, Masafumi ^c   Terao, Akira ^d   Akizawa, Tadao ^e  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JOSAI UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

haemodialysis; hyperphosphataemia; PA21 compound; sevelamer; sucroferric oxyhydroxide

Indexed keywords

BICARBONATE; FERRITIN; HEMOGLOBIN; SEVELAMER; SUCROFERRIC OXYHYDROXIDE; TRANSFERRIN; BIOLOGICAL MARKER; CALCIUM; CHELATING AGENT; DRUG COMBINATION; FERRIC ION; PARATHYROID HORMONE; PHOSPHORUS; PTH PROTEIN, HUMAN; SUCROSE; TABLET;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TABLET; TRANSFERRIN BLOOD LEVEL; ADVERSE EFFECTS; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; HEMODIALYSIS; JAPAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; BIOMARKERS; CALCIUM; CHELATING AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; JAPAN; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVELAMER; SUCROSE; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85015351699     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12891     Document Type: Article

References (19)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004; 15: 2208–2218.
2. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771–780.
3. Fukagawa M, Yokoyama K, Koiwa F et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther. Apher. Dial. 2013; 17: 247–288.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42: S1–S201.
5. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999; 33: 694–701.
6. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther. Apher. Dial. 2008; 12: 514–525.
7. Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther. Apher. Dial. 2014; 18: 122–131.
8. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med. 2010; 362: 1312–1324.
9. Yokoyama K, Akiba T, Fukagawa M et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial. Transplant. 2014; 29: 1053–1060.
10. Floege J, Covic AC, Ketteler M et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014; 86: 638–647.
11. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 2009; 4: 1089–1096.
12. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol. Dial. Transplant. 2014; 29: 2092–2099.
13. Dong R, Guo ZY, Ding JR, Zhou YY, Wu H. Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis. World J. Gastroenterol. 2014; 20: 11370–11375.
14. Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. Curr. Drug Metab. 2014; 15: 953–965.
15. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin. Nephrol. 2010; 74: 4–11.
16. Floege J, Covic AC, Ketteler M et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol. Dial. Transplant. 2015; 30: 1037–1046.
17. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2013; 28: 2570–2579.
18. Bailie GR, Larkina M, Goodkin DA et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015; 87: 162–168.
19. Kraut JA, Nagami GT. The use and interpretation of serum bicarbonate concentration in dialysis patients. Semin. Dial. 2014; 27: 577–579.